Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco NASDAQ 100 ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.24 (market cap $1.98B), while Invesco NASDAQ 100 ETF trades at $295.01. Which is the better fit depends on your goals.
| AMLX | QQQM | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $18.70 | $307.23 |
52-Week Low | $7.64 | $228.02 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
QQQM trades at $298.71, up 0.32% with a bullish technical signal from moving averages. The ETF benefits from Nasdaq 100 exposure, particularly growth-oriented tech stocks, with recent news highlighting SpaceX's inclusion in the index. Support levels are firm at $295 and $293, while resistance sits near $299 and $301.
The outlook remains positive given the ETF's focus on AI-driven growth companies and strong institutional interest. Risks include market volatility and concentration in tech, but long-term growth prospects from sectors like AI infrastructure support a favorable view for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
